查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370901

品牌學名藥市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、按應用、配銷通路、地區、競爭細分

Branded Generics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class, By Application, By Distribution Channel, By Region, By Competition
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球品牌學名藥市場估值達到 2300.2 億美元，預計在預測期內將出現顯著成長，預計到 2028 年年複合成長率 (CAGR) 為 6.25%，2028 年將達到 3332 億美元。2028 年。品牌學名藥（即以不同品牌名稱重新發布的藥品）的採用率有所增加。這些藥物以較低的成本重新推出，雖然形狀、大小、顏色和味道可能有所不同，但藥物的核心保持不變。當藥物專利到期時就會發生這種情況。品牌學名藥包括用於治療高血壓、糖尿病、背痛、甲狀腺問題和關節炎等各種疾病的藥物。他們提供具有成本效益的替代方案，以保持市場競爭力，同時保持相同水準的品質和治療效果。

主要市場促進因素

  • 1.專利到期時間增加：隨著品牌藥的專利到期，學名藥製造商獲得了以其版本進入市場的合法權利。這種競爭往往會導致藥品價格下降，使消費者更能負擔醫療保健費用。此外，它使人們能夠更廣泛地獲得基本藥物，特別是在成本成為障礙的地區，從而擴大了市場。品牌學名藥的價格通常低於品牌學名藥，這可以為醫療保健系統節省大量成本，特別是在醫療保健預算有限的發展中國家或地區。政府和醫療保健提供者可能更願意開處方和購買品牌學名藥，進一步推動市場成長。專利到期後，多家學名藥製造商進入市場會加劇競爭。這種競爭可以推動配方、輸送方法和包裝方面的創新，因為製造商努力使他們的產品與眾不同，以獲得更大的市場佔有率。在某些情況下，專利到期後推出多種學名藥可能會導致市場飽和。因此，由於激烈的競爭，學名藥價格可能會大幅下降，這限制了學名藥製造商的收入潛力，但有利於消費者和醫療保健系統。學名藥市場競爭的加劇可以激勵製造商投資於研發，以提高學名藥產品的品質、功效和安全性。這種對創新的關注可以進一步推動品牌學名藥市場的成長。
市場概況
預測期 2024-2028
2022 年市場規模 2300.2億美元
2028 年市場規模 3332億美元
2023-2028 年年複合成長率 6.25%
成長最快的細分市場 網路藥局
最大的市場 北美洲
  • 2.醫生和患者的接受度不斷提高：醫生對品牌學名藥的認可在其市場成長中發揮關鍵作用。當醫生對品牌學名藥的品質和有效性有信心時，他們更傾向於向患者開藥。醫生的建議和對品牌學名藥療效的信任可以減輕患者對從品牌藥物轉向學名藥的擔憂。醫生在開藥時通常會考慮患者的經濟負擔。如果醫生認為品牌學名藥具有與品牌藥類似的治療效果，他們可能更有可能開立處方藥來幫助患者節省醫療費用。製藥公司和醫療機構可以幫助醫生了解品牌學名藥與品牌藥物的品質、安全性和等效性。適當的教育可以積極影響醫生的接受度和處方習慣。患者可能會對從知名品牌藥物過渡到學名藥感到猶豫。品牌學名藥的正面體驗和成功治療結果可以增強患者對其有效性的信心，從而提高接受度。患者通常相信醫生的建議。如果醫生解釋品牌學名藥的優勢，包括其價格實惠和同等的治療效果，患者就更有可能接受它們。成本考慮大大提高了患者的接受度。無力負擔昂貴品牌藥物的患者可能更願意使用品牌學名藥，只要他們能保證其安全性和有效性。
  • 3.慢性病發生率上升：全球慢性病發生率不斷上升，導致對治療這些疾病的藥物的需求不斷成長。品牌學名藥為品牌藥提供了具有成本效益的替代品，使更多需要持續治療的患者更容易獲得它們。慢性病通常需要長期的藥物治療，這可能會對患者造成經濟負擔。品牌學名藥比品牌學名藥更實惠，對於希望在不增加財務壓力的情況下控制病情的患者來說是一個可行的選擇。政府和醫療保健系統面臨著提供負擔得起且永續的醫療保健服務的壓力，特別是在管理慢性病方面。品牌學名藥透過提供具有成本效益的治療方案，幫助醫療保健系統更有效地管理預算。對治療慢性疾病的藥物的需求為製藥公司創造了競爭格局。用於治療慢性病的品牌藥物的專利到期為學名藥製造商以其品牌學名藥進入市場提供了機會。這種競爭可以帶來配方、給藥方法和包裝的創新，從而促進品牌學名藥市場的成長。慢性病影響著全世界的人口，全球品牌學名藥市場的成長與已開發國家和發展中國家對慢性病可及且負擔得起的治療方案的需求相一致。由於生活方式的改變和人口老化，許多慢性病在新興市場變得越來越普遍。品牌學名藥滿足了這些地區對具有成本效益的治療的需求，推動了市場成長。

主要市場挑戰

  • 1.監管障礙：學名藥，包括品牌學名藥，必須經過法規核准程序，以確保其安全性、品質和有效性。核准過程中的延遲或複雜性可能會減慢新品牌學名藥產品推向市場的速度。監管機構通常對證明品牌學名藥與其品牌同類藥物的生物等效性有嚴格的要求。滿足這些要求可能具有挑戰性且耗時，可能會導致市場准入延遲。處理原始品牌藥物的專利時可能會出現監管挑戰。即使在專利到期後，專利糾紛和法律訴訟也可能會延遲或阻止品牌學名藥的上市。不同國家對學名藥有不同的監管架構和要求。對於希望在全球範圍內銷售品牌學名藥的製藥公司來說，應對這些不同的法規可能會很複雜。確保一致的品質和遵守製造標準對於學名藥的接受至關重要。與品質控制相關的監管障礙可能會影響醫療保健專業人員和患者對品牌學名藥的看法和信任。一些監管體系為創新藥物提供資料獨佔期或市場獨佔期，這可能會延遲學名藥替代品的進入。這可能會阻礙品牌學名藥的供應，尤其是在獨佔期較長的市場中。
  • 2.不斷變化的醫療保健政策：政府經常實施定價法規來控制醫療保健成本並確保病人的負擔能力。雖然這些法規可能導致藥品價格下降，但它們也會影響學名藥製造商的獲利能力，包括那些生產品牌學名藥的製造商。如果定價法規導致利潤率極低，製造商可能會不願意生產或推廣品牌學名藥。報銷政策決定了保險或政府醫療保健計劃可以支付多少藥物費用。報銷政策的變化，例如品牌學名藥報銷率的降低，可能會影響患者對這些產品的取得和需求。醫療保健政策可以影響處方集中特定藥物的包含或排除，處方集是保險計劃或醫療保健系統涵蓋的藥物清單。如果品牌學名藥因政策變化而被排除在處方集之外，可能會限制其市場範圍和成長潛力。一些醫療保健政策和指南鼓勵使用學名藥而不是品牌藥以降低成本。雖然這可以使醫療保健系統和患者受益，但它可能會影響品牌學名藥的市場潛力，品牌學名藥被定位為品牌藥和學名藥之間的橋樑。與市場獨佔性相關的智慧財產權法或政策的變化可能會影響品牌學名藥的競爭格局。如果政策延長品牌藥物的市場獨佔期，則可能會延遲學名藥替代品（包括品牌學名藥）的進入。與平行進口（從低成本市場進口和銷售品牌學名藥）相關的政策變化可能會影響某些地區品牌學名藥的供應和定價。缺乏清晰度或透明度的醫療保健政策可能會導致患者和醫療保健專業人員感到困惑。這種混亂可能

影響患者和醫生對品牌學名藥的接受度，阻礙其市場成長。

主要市場趨勢

  • 1.數位健康整合的進步：數位健康技術的整合可以透過提供藥物提醒、追蹤和依從性工具來增強患者的參與度。品牌學名藥價格更實惠，可以從患者參與度的增加中受益，從而改善治療結果和患者忠誠度。品牌學名藥通常用於管理慢性病，而數位健康解決方案可以遠端監控患者的健康狀況，這是慢性病管理的重要功能。這種整合可以提高患者對藥物治療方案的依從性，有助於品牌學名藥市場的成長。數位健康平台可以促進遠距醫療諮詢，醫生可以遠端診斷和開藥，包括品牌學名藥。這可以增加患者獲得這些藥物的機會，特別是在醫療基礎設施有限的地區。數位健康解決方案可以根據患者資料和健康指標制定個人化治療計劃，根據患者個別需求定製品牌學名藥，從而獲得更好的治療結果和患者滿意度。數位健康整合還可以提高患者和醫療保健提供者對品牌學名藥的認知。製造商可以使用數位平台向用戶宣傳品牌學名藥的優勢、可用性和成本節約。製藥公司可以利用資料分析來深入了解市場趨勢、患者偏好和醫療保健利用模式，從而指導品牌學名藥的行銷策略和產品定位。
  • 2.品牌學名藥領域生物相似藥的發展：在某些情況下，生物相似藥既與原廠生物藥也與品牌學名藥競爭。這種競爭可能會導致價格下降，使患者能夠更負擔得起治療，並對品牌學名藥的定價施加壓力，從而由於節省成本而增加其採用率。生物相似藥可以透過為原本無法負擔生物治療費用的患者提供更實惠的選擇來擴大市場，透過提高對具有成本效益的替代品的認知和需求來使品牌學名藥受益。生物相似藥可以佔據原廠生物製劑和品牌學名藥的部分市場佔有率，根據競爭格局，可能會影響品牌學名藥市場的成長。生物相似藥的引入可以增加圍繞生物製劑及其替代品的教育力度，這可以透過創建一個更知情的市場來了解具有成本效益的選擇的價值，從而使品牌學名藥受益。為生物相似藥制定的監管途徑也會影響學名藥（包括品牌學名藥）的監管。隨著患者越來越熟悉生物相似藥及其益處，他們可能會更願意考慮替代治療方案，包括品牌學名藥。患者的偏好和接受度可能會受到生物相似藥採用的更廣泛背景的影響。

細分市場洞察

藥品類別洞察：在藥品類別領域，抗高血壓類別預計在整個預測期內將大幅市場成長。造成這種成長的因素有很多，包括高血壓作為影響數百萬人的重大健康問題的全球盛行率。久坐的生活方式和不健康的飲食導致高血壓病例持續上升。品牌學名藥提供了一種有效的解決方案，為品牌抗高血壓藥物提供負擔得起的替代品。鑑於高血壓是一種慢性疾病，通常需要終生服藥，品牌學名藥透過提供具有成本效益的選擇來滿足持續治療的需求。北美高昂的醫療費用推動了對品牌藥物更實惠的替代品的需求。品牌學名藥為患者和醫療保健系統提供了一種經濟高效的選擇，有助於他們在該地區的成長。品牌學名藥滿足了對可獲取藥物的需求，特別是針對北美流行的慢性疾病。他們幫助患者管理自己的病情，而無需承擔昂貴品牌藥物的經濟負擔。北美健康保險系統的存在，包括私人保險和醫療保險和醫療補助等政府計劃，可以透過為這些藥物提供保險來鼓勵使用更實惠的品牌學名藥。

配銷通路洞察：零售藥房領域一直是配銷通路類別市場的主導力量。零售藥局在向患者分發藥物（包括品牌學名藥）方面發揮著至關重要的作用。藥房貨架上的品牌學名藥使尋求負擔得起的治療選擇的患者可以輕鬆獲得它們。零售藥局的藥劑師向患者提供有關其藥物的資訊，包括品牌學名藥。他們可以教育患者了解品牌學名藥的好處、成本節約和有效性，影響他們的看法和接受度。零售藥局經常與保險公司和醫療保健系統合作建立處方集，即批准的藥物清單。將品牌學名藥涵蓋這些處方集可以導致處方數量增加和市場成長。零售藥局適應患者的財務限制。透過提供品牌學名藥作為更實惠的替代品，藥局有助於患者獲得藥物並堅持用藥。在擁有大量零售藥房的新興市場，品牌學名藥對於為大量人群提供負擔得起的治療選擇至關重要。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球品牌學名藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（烷化劑、抗代謝藥、荷爾蒙、抗高血壓藥、降血脂藥、抗憂鬱藥、抗精神病藥、抗癲癇藥等）
    • 按應用（腫瘤、心血管疾病、神經系統疾病、急性慢性疼痛、胃腸道疾病、皮膚病、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
    • 按公司分類 (2022)
  • 市場地圖
    • 按藥物類別
    • 按應用
    • 按配銷通路
    • 按地區

第 6 章：北美品牌學名藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（烷化劑、抗代謝藥、荷爾蒙、抗高血壓藥、降血脂藥、抗憂鬱藥、抗精神病藥、抗癲癇藥等）
    • 按應用（腫瘤、心血管疾病、神經系統疾病、急性慢性疼痛、胃腸道疾病、皮膚病、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲品牌學名藥市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（烷化劑、抗代謝藥、荷爾蒙、抗高血壓藥、降血脂藥、抗憂鬱藥、抗精神病藥、抗癲癇藥等）
    • 按應用（腫瘤、心血管疾病、神經系統疾病、急性慢性疼痛、胃腸道疾病、皮膚病、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區品牌學名藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（烷化劑、抗代謝藥、荷爾蒙、抗高血壓藥、降血脂藥、抗憂鬱藥、抗精神病藥、抗癲癇藥等）
    • 按應用（腫瘤、心血管疾病、神經系統疾病、急性慢性疼痛、胃腸道疾病、皮膚病、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲品牌學名藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（烷化劑、抗代謝藥、荷爾蒙、抗高血壓藥、降血脂藥、抗憂鬱藥、抗精神病藥、抗癲癇藥等）
    • 按應用（腫瘤、心血管疾病、神經系統疾病、急性慢性疼痛、胃腸道疾病、皮膚病、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲品牌學名藥市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（烷化劑、抗代謝藥、荷爾蒙、抗高血壓藥、降血脂藥、抗憂鬱藥、抗精神病藥、抗癲癇藥等）
    • 按應用（腫瘤、心血管疾病、神經系統疾病、急性慢性疼痛、胃腸道疾病、皮膚病、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按國家/地區
  • MEA：國家分析
    • 南非品牌學名藥
    • 沙烏地阿拉伯品牌學名藥
    • 阿拉伯聯合大公國品牌學名藥

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球品牌學名藥市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 產品供應
  • 最近的發展
  • 財務（據報導）
  • 主要人員
  • SWOT分析
    • Teva Pharmaceutical Industries Ltd.
    • Lupin Pharmaceuticals Inc.
    • Sanofi-Aventis.
    • Sun Pharmaceutical Industries Inc.
    • Dr Reddy's Laboratories Inc.
    • Endo International PLC.
    • GlaxoSmithKline LLC.
    • Pfizer Inc.
    • Viatris Inc.
    • Apotex Inc.

第 16 章：策略建議

簡介目錄
Product Code: 17112

The Global Branded Generics Market achieved a valuation of USD 230.02 Billion in 2022, and it is poised for remarkable growth in the forecast period, with an expected Compound Annual Growth Rate (CAGR) of 6.25% through 2028 and expected to reach USD 333.20 Billion in 2028. Branded generics, which are pharmaceutical drugs re-released under different brand names, have seen increased adoption. These medicines are reintroduced at a lower cost, and while the shape, size, color, and flavor may vary, the medication's core remains the same. This happens when the patent for the drug has expired. Branded generics encompass drugs used to treat various conditions like hypertension, diabetes, back pain, thyroid issues, and arthritis. They offer cost-effective alternatives to stay competitive in the market while maintaining the same level of quality and therapeutic effectiveness.

Key Market Drivers

  • 1. Rising Patent Expirations: As the patents of branded drugs expire, generic drug manufacturers gain the legal right to enter the market with their versions. This competition often leads to lower drug prices, making healthcare more affordable for consumers. Moreover, it enables wider access to essential medications, particularly in regions where cost was a barrier, thereby expanding the market. Branded generics are typically priced lower than their branded counterparts, which can yield significant savings for healthcare systems, especially in developing countries or regions with constrained healthcare budgets. Governments and healthcare providers may prefer to prescribe and procure branded generics, further driving market growth. Multiple generic manufacturers entering the market after a patent expiration fosters increased competition. This competition can fuel innovation in terms of formulation, delivery methods, and packaging as manufacturers strive to differentiate their products to gain a larger market share. In some cases, the introduction of numerous generic versions of a drug post-patent expiry can lead to market saturation. Consequently, generic drug prices can significantly decrease due to intense competition, which limits the revenue potential for generic manufacturers but benefits consumers and healthcare systems. The heightened competition in the generic market can incentivize manufacturers to invest in research and development to improve the quality, efficacy, and safety of their generic products. This focus on innovation can further drive the growth of the branded generics market.
Market Overview
Forecast Period2024-2028
Market Size 2022USD 230.02 Billion
Market Size 2028USD 333.20 Billion
CAGR 2023-20286.25%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America
  • 2. Growing Acceptance by Physicians and Patients: Physician endorsement of branded generics plays a pivotal role in their market growth. When physicians have confidence in the quality and effectiveness of branded generics, they are more inclined to prescribe them to their patients. Physician recommendations and trust in the efficacy of branded generics can alleviate patient concerns about switching from branded drugs to their generic counterparts. Physicians often consider the financial burden on their patients when prescribing medications. If physicians believe that branded generics offer similar therapeutic benefits to branded drugs, they may be more likely to prescribe them to help patients save on healthcare costs. Pharmaceutical companies and healthcare institutions can contribute to educating physicians about the quality, safety, and equivalence of branded generics compared to branded drugs. Proper education can positively influence physicians' acceptance and prescribing habits. Patients may be hesitant about transitioning from well-known branded medications to generic versions. Positive experiences and successful treatment outcomes with branded generics can build patients' confidence in their effectiveness, leading to increased acceptance. Patients often trust their physicians' recommendations. If physicians explain the advantages of branded generics, including their affordability and equivalent therapeutic effects, patients are more likely to accept them. Cost considerations significantly drive patient acceptance. Patients unable to afford expensive branded medications may be more open to using branded generics as long as they are assured of their safety and efficacy.
  • 3. Rising Incidence of Chronic Diseases: The increasing global incidence of chronic diseases has generated a growing demand for medications to manage these conditions. Branded generics offer cost-effective alternatives to branded drugs, making them more accessible to a larger population of patients requiring continuous treatment. Chronic diseases often necessitate long-term medication regimens, which can become financially burdensome for patients. Branded generics, being more affordable than their branded counterparts, are a viable option for patients looking to manage their conditions without straining their finances. Governments and healthcare systems face pressure to provide affordable and sustainable healthcare services, especially for managing chronic diseases. Branded generics help healthcare systems manage their budgets more efficiently by offering cost-effective treatment options. The demand for medications to manage chronic diseases creates a competitive landscape for pharmaceutical companies. The expiration of patents for branded drugs used to manage chronic diseases opens up opportunities for generic manufacturers to enter the market with their branded generic versions. This competition can lead to innovation in formulations, delivery methods, and packaging, thereby enhancing the growth of the branded generics market. Chronic diseases affect populations worldwide, and the growth of the global branded generics market aligns with the need for accessible and affordable treatment options for chronic diseases in both developed and developing countries. Many chronic diseases are becoming increasingly prevalent in emerging markets due to lifestyle changes and aging populations. Branded generics address the demand for cost-effective treatments in these regions, driving market growth.

Key Market Challenges

  • 1. Regulatory Hurdles: Generic medications, including branded generics, must undergo regulatory approval processes to ensure their safety, quality, and efficacy. Delays or complexities in the approval process can slow down the introduction of new branded generic products to the market. Regulatory authorities often have strict requirements for demonstrating the bioequivalence of branded generics to their branded counterparts. Meeting these requirements can be challenging and time-consuming, potentially causing delays in market entry. Regulatory challenges can arise when dealing with the patents of the original branded drugs. Patent disputes and legal battles can delay or prevent the launch of branded generics even after the patent has expired. Different countries have varying regulatory frameworks and requirements for generic medications. Navigating these diverse regulations can be complex for pharmaceutical companies looking to market branded generics globally. Ensuring consistent quality and adherence to manufacturing standards is crucial for the acceptance of generic medications. Regulatory hurdles related to quality control can affect the perception and trust of healthcare professionals and patients in branded generics. Some regulatory systems offer periods of data exclusivity or market exclusivity for innovator drugs, which can delay the entry of generic alternatives. This can hinder the availability of branded generics, especially in markets with longer exclusivity periods.
  • 2. Changing Healthcare Policies: Governments often implement pricing regulations to control healthcare costs and ensure affordability for patients. While these regulations can lead to lower prices for medications, they can also impact the profitability of generic manufacturers, including those producing branded generics. If pricing regulations result in extremely low profit margins, manufacturers might be discouraged from producing or promoting branded generics. Reimbursement policies determine how much of the cost of a medication is covered by insurance or government healthcare programs. Changes in reimbursement policies, such as reduced reimbursement rates for branded generics, can influence patient access and demand for these products. Healthcare policies can influence the inclusion or exclusion of specific medications on formularies, which are lists of drugs covered by insurance plans or healthcare systems. If branded generics are excluded from formularies due to policy changes, it can limit their market reach and growth potential. Some healthcare policies and guidelines encourage the use of generic medications over branded drugs to reduce costs. While this can benefit the healthcare system and patients, it might impact the market potential for branded generics, which are positioned as a bridge between branded and generic drugs. Changes in intellectual property laws or policies related to market exclusivity can affect the competitive landscape for branded generics. If policies extend market exclusivity periods for branded drugs, it can delay the entry of generic alternatives, including branded generics. Changing policies related to parallel imports (importing and selling branded generics from lower-cost markets) can impact the availability and pricing of branded generics in certain regions. Healthcare policies that lack clarity or transparency can lead to confusion among patients and healthcare professionals. This confusion might

affect patient and physician acceptance of branded generics, hindering their market growth.

Key Market Trends

  • 1. Advancements in Digital Health Integration: The integration of digital health technologies can enhance patient engagement by offering tools for medication reminders, tracking, and adherence. Branded generics, being more affordable, can benefit from increased patient engagement, leading to improved treatment outcomes and patient loyalty. Branded generics are often used for managing chronic diseases, and digital health solutions enable remote monitoring of patients' health conditions, a valuable feature for chronic disease management. This integration can improve patient compliance with medication regimens, contributing to the growth of the branded generics market. Digital health platforms can facilitate telemedicine consultations, where physicians can remotely diagnose and prescribe medications, including branded generics. This can increase the accessibility of these medications to patients, especially in regions with limited healthcare infrastructure. Digital health solutions can enable personalized treatment plans based on patient data and health metrics, tailoring branded generics to individual patient needs, resulting in better treatment outcomes and patient satisfaction. Digital health integration can also improve awareness of branded generics among patients and healthcare providers. Manufacturers can use digital platforms to educate users about the benefits, availability, and cost savings associated with branded generics. Pharmaceutical companies can employ data analytics to gain insights into market trends, patient preferences, and healthcare utilization patterns, guiding marketing strategies and product positioning for branded generics.
  • 2. Development of Biosimilars in the Branded Generics Landscape: Biosimilars compete with both original biologic drugs and branded generics in some cases. This competition can lead to lower prices, making treatment more affordable for patients and putting pressure on the pricing of branded generics, thereby increasing their adoption due to cost savings. Biosimilars can expand the market by providing more affordable options for patients who might have otherwise been unable to afford biologic treatments, benefiting branded generics by raising awareness and demand for cost-effective alternatives. Biosimilars can capture a portion of the market share of both original biologics and branded generics, potentially impacting the growth of the branded generics market depending on the competitive landscape. The introduction of biosimilars can lead to increased education efforts around biologics and their alternatives, which can benefit branded generics by creating a more informed market that understands the value of cost-effective options. Regulatory pathways developed for biosimilars can also impact regulations around generic medications, including branded generics. As patients become more familiar with biosimilars and their benefits, they might become more open to considering alternative treatment options, including branded generics. Patient preferences and acceptance can be influenced by the broader context of biosimilar adoption.

Segmental Insights

Drug Class Insights: Within the Drug Class segment, the Anti-Hypertensive category is expected to witness substantial market growth throughout the forecast period. Several factors contribute to this growth, including the global prevalence of hypertension as a significant health concern affecting millions of individuals. Sedentary lifestyles and unhealthy diets have led to a continuous rise in hypertension cases. Branded generics offer an effective solution by providing affordable alternatives to branded anti-hypertensive drugs. Given that hypertension is a chronic condition often requiring lifelong medication, branded generics address the need for continuous treatment by offering cost-effective options. The high healthcare costs in North America have driven the demand for more affordable alternatives to branded drugs. Branded generics provide a cost-effective option for patients and healthcare systems, contributing to their growth in the region. Branded generics address the need for accessible medications, particularly for chronic diseases that are prevalent in North America. They help patients manage their conditions without the financial burden of expensive branded medications. The presence of health insurance systems in North America, including private insurance and government programs like Medicare and Medicaid, can encourage the use of more affordable branded generics by providing coverage for these medications.

Distribution Channel Insights: The Retail Pharmacy segment has been the dominant force in the market within the Distribution Channel category. Retail pharmacies play a crucial role in distributing medications, including branded generics, to patients. The availability of branded generics on pharmacy shelves makes them readily accessible to patients seeking affordable treatment options. Pharmacists at retail pharmacies provide patients with information about their medications, including branded generics. They can educate patients about the benefits, cost savings, and effectiveness of branded generics, influencing their perception and acceptance. Retail pharmacies often collaborate with insurance companies and healthcare systems to establish formularies, which are lists of approved medications. Including branded generics in these formularies can lead to increased prescriptions and market growth. Retail pharmacies are attuned to patients' financial constraints. By offering branded generics as more affordable alternatives, pharmacies contribute to patient access and adherence to medications. In emerging markets with a significant retail pharmacy presence, branded generics can become essential for providing affordable treatment options to large populations.

Regional Insights: North America, specifically the Branded Generics Market, dominated the market in 2022. North America has seen a significant number of patent expirations for blockbuster drugs, creating opportunities for generic manufacturers to introduce branded generic versions. As a result, the region has experienced substantial growth in the branded generics market as companies capitalize on these opportunities. The high healthcare costs in North America have driven the demand for more affordable alternatives to branded drugs. Branded generics provide a cost-effective option for patients and healthcare systems, contributing to their growth in the region. Branded generics address the need for accessible medications, particularly for chronic diseases that are prevalent in North America. They help patients manage their conditions without the financial burden of expensive branded medications. The presence of health insurance systems in North America, including private insurance and government programs like Medicare and Medicaid, can encourage the use of more affordable branded generics by providing coverage for these medications.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals Inc.
  • Sanofi-Aventis.
  • Sun Pharmaceutical Industries Inc.
  • Dr Reddy's Laboratories Inc.
  • Endo International PLC.
  • GlaxoSmithKline LLC.
  • Pfizer Inc.
  • Viatris Inc.
  • Apotex Inc.

Report Scope:

In this report, the Global Branded Generics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Branded Generics Market, By Drug Class:

  • Alkylating Agents
  • Antimetabolites, Hormones
  • Anti - Hypertensive
  • Lipid Lowering Drugs
  • Antidepressants
  • Antipsychotics
  • Antiepileptics
  • Others

Branded Generics Market, By Application:

  • Oncology
  • Cardiovascular Diseases
  • Neurological Diseases
  • Acute & Chronic Pain
  • Gastrointestinal Diseases
  • Dermatological Diseases
  • Others

Branded Generics Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Branded Generics Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Branded Generics Market.

Available Customizations:

  • Global Branded Generics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Branded Generics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
    • 5.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.5. By Company (2022)
  • 5.3. Market Map
    • 5.3.1 By Drug Class
    • 5.3.2 By Application
    • 5.3.3 By Distribution Channel
    • 5.3.4 By Region

6. North America Branded Generics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
    • 6.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
    • 6.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Branded Generics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Branded Generics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Branded Generics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Distribution Channel

7. Europe Branded Generics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
    • 7.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
    • 7.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Branded Generics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Germany Branded Generics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Branded Generics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Branded Generics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Branded Generics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Branded Generics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
    • 8.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
    • 8.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Branded Generics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Branded Generics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Branded Generics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Branded Generics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Branded Generics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Distribution Channel

9. South America Branded Generics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
    • 9.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
    • 9.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Branded Generics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Branded Generics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Branded Generics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Branded Generics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
    • 10.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
    • 10.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Branded Generics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Branded Generics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Branded Generics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Branded Generics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Financials (As Reported)
  • 15.5. Key Personnel
  • 15.6. SWOT Analysis
    • 15.6.1 Teva Pharmaceutical Industries Ltd.
    • 15.6.2 Lupin Pharmaceuticals Inc.
    • 15.6.3 Sanofi-Aventis.
    • 15.6.4 Sun Pharmaceutical Industries Inc.
    • 15.6.5 Dr Reddy's Laboratories Inc.
    • 15.6.6 Endo International PLC.
    • 15.6.7 GlaxoSmithKline LLC.
    • 15.6.8 Pfizer Inc.
    • 15.6.9 Viatris Inc.
    • 15.6.10 Apotex Inc.

16. Strategic Recommendations